QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)
QQQ   416.86 (-1.55%)
AAPL   165.06 (-1.19%)
MSFT   399.22 (-1.25%)
META   482.94 (-3.76%)
GOOGL   153.46 (-1.63%)
AMZN   174.74 (-2.50%)
TSLA   148.86 (-0.71%)
NVDA   809.73 (-4.37%)
AMD   148.29 (-4.38%)
NIO   3.82 (-4.50%)
BABA   68.65 (-0.33%)
T   16.37 (+0.24%)
F   12.11 (+0.41%)
MU   107.40 (-4.05%)
GE   148.66 (-2.80%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.29 (+12.67%)
PFE   25.79 (+1.58%)
PYPL   62.13 (+0.05%)
XOM   120.02 (+1.27%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$5.41
+0.4%
$6.69
$4.05
$10.80
$146.45M0.89147,833 shs74,953 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.16
$1.15
$0.98
$1.89
$36.26M-0.6866,386 shs4,871 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$7.96
+2.2%
$0.00
$7.75
$11.44
$169.23M1.2444,389 shs6,250 shs
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$67.75
+0.8%
$70.17
$66.90
$100.59
$243.22M0.1226,572 shs18,266 shs
The Westaim Co. stock logo
WEDXF
Westaim
$2.67
-0.4%
$2.66
$2.13
$2.99
$345.65M0.4635,746 shs6,571 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-2.53%-13.06%-22.78%-28.23%-46.79%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+1.75%-6.45%+5.45%-4.92%-22.15%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.00%0.00%0.00%0.00%-6.84%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
-0.58%-4.18%-2.41%-17.81%-29.23%
The Westaim Co. stock logo
WEDXF
Westaim
-0.37%+1.16%-2.91%-1.48%+21.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
2.1343 of 5 stars
3.54.00.00.02.70.00.6
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.7393 of 5 stars
3.02.00.04.40.60.00.6
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
1.5288 of 5 stars
0.04.00.04.03.02.50.0
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
3.3733 of 5 stars
0.05.01.74.23.01.71.3
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$12.00121.81% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50115.52% Upside
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest CLPT, CODX, INFU, UTMD, and WEDXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/13/2024
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $9.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$23.95M6.11N/AN/A$0.86 per share6.29
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.32N/AN/A$2.81 per share0.41
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$125.79M1.35$0.64 per share12.35$2.47 per share3.22
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$50.22M4.84$6.35 per share10.67$35.35 per share1.92
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M39.90$1.40 per share1.91$3.95 per share0.68

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$22.09M-$0.91N/AN/AN/A-92.21%-83.94%-47.92%5/9/2024 (Estimated)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.03265.42N/A0.69%1.73%0.85%N/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$16.64M$4.5714.82N/A33.12%13.53%12.68%4/23/2024 (Estimated)
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.05N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest CLPT, CODX, INFU, UTMD, and WEDXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/12/2024Q4 2023
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.22-$0.19+$0.03-$0.19$6.40 million$6.81 million
1/30/2024Q4 2023
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A$1.18+$1.18$1.18N/A$12.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$1.201.77%+1.75%26.26%2 Years
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Latest CLPT, CODX, INFU, UTMD, and WEDXF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
quarterly$0.301.6%3/14/20243/15/20244/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
0.47
4.87
3.80
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.56
1.95
1.54
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A
22.56
20.53
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
69.60%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.11%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
18.50%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
6.50%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
10727.07 million25.42 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
42021.26 million17.33 millionNot Optionable
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
1693.59 million3.36 millionNot Optionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.97 million123.54 millionNot Optionable

CLPT, CODX, INFU, UTMD, and WEDXF Headlines

SourceHeadline
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM
Heres what Wall Street expects from Westaims earnings reportHere's what Wall Street expects from Westaim's earnings report
markets.businessinsider.com - April 6 at 12:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ClearPoint Neuro logo

ClearPoint Neuro

NASDAQ:CLPT
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
InfuSystem logo

InfuSystem

NYSEAMERICAN:INFU
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Utah Medical Products logo

Utah Medical Products

NASDAQ:UTMD
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.